Safety and Efficacy of YH14617 in Diabetes Mellitus

Summary

The objective of this study is to assess the safety, efficacy and pharmacokinetic of YH14617 after once weekly or biweekly injection in patients with type 2 Diabetes Mellitus to investigate the optimal recommended dosage. Study period is 20 weeks including 12 weeks of treatment period and 8weeks of follow-up period without treatment.

Timeline

Start

2011-12

Primary completion

2015-01

Completion

2015-02

Drugs

Indications